entertainment -WSS

entertainment

author：knowledge 2025-09-30 12:10:50 - browse：67885

A follow-up study of a first-of-its-kind cancer treatment may reflect systemic biases, the Food and Drug Administration said ahead of an advisory committee meeting Thursday to determine whether the drug should remain on the market.

The treatment, Lumakras, is designed to treat lung cancer caused by a specific genetic mutation to a protein called KRAS. It’s one of the most common genetic mutations in cancer, but repeated clinical trial failures had led researchers to deem it “undruggable” until a glimmer of hope came about a decade ago.

Lumakras received an accelerated, or conditional, approval in May 2021, making it the first KRAS drug on the market. Now, the drug’s manufacturer, Amgen, needs to prove it works.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Apple is now the first public company to be valued at $3 trillion
Next article： Tuskegee Airman Raymond Cassagnol dies at 102

WSS

The strange history of BMI, the body mass index

Why do we get seasonal allergies?

Readout Newsletter: Merck, J&J, and long Covid

The simple reason for the increase in autism diagnosis

Prior authorization will have to move faster under new Biden rule

Federal board approves $12.7 billion budget for Puerto Rico as island shakes off bankruptcy

focus

entertainment

entertainment

Hollywood unions extend contract negotiations for actors

What Wagner Group's armed rebellion could mean for Russia's endgame in Ukraine

Duchenne breakthrough therapy leaves behind pioneering families

Anger, defiance, fear over Supreme Court decision to block student loan forgiveness

Medical leaders decry Supreme Court decision on affirmative action

Copay coupons to count toward deductibles, after Biden court move

Medical leaders decry Supreme Court decision on affirmative action

Independent physicians launch a new lobbying group

State Dept. review finds Biden bears some blame for Afghanistan failures

Medical experts exlpore how to eliminate bias in clinical algorithms

leisure time

eGenesis tests gene

The strange history of BMI, the body mass index

Ukrainian soldiers say they owe lives to US

Biotech venture capitalists face new demands from investors

Synthetic human embryos? Researchers say term is overblown

EU regulator recommends expanding Mounjaro approval to obesity

leisure time

entertainment

explore

Wikipedia